China's Sinovac Sees Profits Plummet In Wake Of Public Fears Following Vaccine Scandals By Other Producers
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's leading vaccine developer, Sinovac Biotech, posted a steep fall in profits for the second quarter, and revealed that the World Health Organization is working with Chinese regulators on monitoring good manufacturing practice standards following a series of scandals that have hurt the entire sector
You may also be interested in...
Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?
BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet
Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?
BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
BEIJING - Despite posting a sizeable loss in earnings for the second quarter of this year, GlaxoSmithKline is pumping new funds into its recently established joint venture in southern China in a move aimed at profiting from China's healthy economic growth despite the financial ailments that have plagued the Western world